Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
The latest drug development news and highlights from our US FDA Performance Tracker.
Big Launch Year Coming Up In US For Sun But Spends High Too
Sun Pharma, India's top-ranked drug firm, has three key specialty launches lined up in the US in FY19. Management commentary was generally upbeat about the potential prospects of the three products, but also emphasized that the commercialization plans will entail significant costs.
Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark
US FDA's latest BTD awards go to Seattle Genetics and Astellas' antibody-drug conjugate for immunotherapy-experienced urothelial cancer, Fennec's supportive care product to reduce cisplatin ototoxicity in pediatric cancer patients, and Bristol's double immunotherapy combo in MSI-H colorectal cancer.